

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 03/14407

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/005 C07K7/06 C07K19/00 C12N15/63 C12N15/62  
C12N15/33 A61K38/08 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPQ-Internal, WPI Data, Sequence Search, CHEM ABS Data, BIOSIS, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	NICKLIN SA ET AL.: "Selective Targeting of Gene Transfer to Vascular Endothelial Cells by Use of Peptides Isolated by Phage Display" CIRCULATION, vol. 102, 2000, pages 231-237, XP002282540 the entire document, in particular page 231, table 2 and page 235, left-hand column  ----- -/--	1-35

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

28 May 2004

Date of mailing of the international search report

08.09.2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Schmidt, Harald

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 03/14407

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WHITE SJ ET AL: "Identification of peptides that target the endothelial cell-specific LOX-1 receptor" HYPERTENSION, vol. 37, no. 2, February 2001 (2001-02), pages 449-455, XP002959152 ISSN: 0194-911X the entire document, in particular page 449, page 452 (table) and discussion	1-35
A	WO 00/73478 A (SHAYAKHMETOV DMITRY ; FARRAR DENISE (US); LIEBER ANDRE (US); UNIV WASH) 7 December 2000 (2000-12-07) page 6	1-35
P,A	US 2003/149235 A1 (BAKER ANDREW HOWARD ET AL) 7 August 2003 (2003-08-07) the whole document	1-35

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 03/14407

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claim 35 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-35 (all partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claim 35 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-35 (all partially)

peptide consisting of SEQ ID NO:1, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

2. claims: 1-35 (all partially)

peptide consisting of SEQ ID NO:2, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

3. claims: 1-35 (all partially)

peptide consisting of SEQ ID NO:3, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

4. claims: 1-35 (all partially)

peptide consisting of SEQ ID NO:4, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

5. claims: 1-35 (all partially)

peptide consisting of SEQ ID NO:5, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

6. claims: 1-35 (all partially)

peptide consisting of SEQ ID NO:6, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

7. claims: 1,3-35 (all partially)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

peptide consisting of SEQ ID NO:7, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

8. claims: 1,3-35 (all partially)

peptide consisting of SEQ ID NO:8, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

9. claims: 1,3-35 (all partially)

peptide consisting of SEQ ID NO:9, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

10. claims: 1,3-35 (all partially)

peptide consisting of SEQ ID NO:10, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

11. claims: 1,3-35 (all partially)

peptide consisting of SEQ ID NO:11, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

12. claims: 1,3-35 (all partially)

peptide consisting of SEQ ID NO:12, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

13. claims: 1,3-35 (all partially)

peptide consisting of SEQ ID NO:13, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

14. claims: 1,3-35 (all partially)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

peptide consisting of SEQ ID NO:14, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

15. claims: 1,3-35 (all partially)

peptide consisting of SEQ ID NO:15, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

16. claims: 1,3-35 (all partially)

peptide consisting of SEQ ID NO:16, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

17. claims: 1,3-35 (all partially)

peptide consisting of SEQ ID NO:17, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

18. claims: 1,3-35 (all partially)

peptide consisting of SEQ ID NO:18, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

19. claims: 1,3-35 (all partially)

peptide consisting of SEQ ID NO:19, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

20. claims: 1,3-35 (all partially)

peptide consisting of SEQ ID NO:20, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

21. claims: 1,3-35 (all partially)

peptide consisting of SEQ ID NO:21, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

22. claims: 1,3-35 (all partially)

peptide consisting of SEQ ID NO:22, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

23. claims: 1,3-35 (all partially)

peptide consisting of SEQ ID NO:23, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

24. claims: 1,3-35 (all partially)

peptide consisting of SEQ ID NO:24, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

25. claims: 1,3-35 (all partially)

peptide consisting of SEQ ID NO:25, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

26. claims: 1,3-35 (all partially)

peptide consisting of SEQ ID NO:26, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

27. claims: 1,3-35 (all partially)

peptide consisting of SEQ ID NO:27, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---



## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

28. claims: 1,3-35 (all partially)

peptide consisting of SEQ ID NO:28, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

29. claims: 1,3-35 (all partially)

peptide consisting of SEQ ID NO:29, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

30. claims: 1,3-35 (all partially)

peptide consisting of SEQ ID NO:30, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

31. claims: 1,3-35 (all partially)

peptide consisting of SEQ ID NO:31, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

32. claims: 1,3-35 (all partially)

peptide consisting of SEQ ID NO:32, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

33. claims: 1,3-35 (all partially)

peptide consisting of SEQ ID NO:33, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

34. claims: 1,3-35 (all partially)

peptide consisting of SEQ ID NO:34, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

---  
35. claims: 1,3-35 (all partially)

peptide consisting of SEQ ID NO:35, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

36. claims: 1,3-35 (all partially)

peptide consisting of SEQ ID NO:36, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

37. claims: 1,3-35 (all partially)

peptide consisting of SEQ ID NO:37, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

38. claims: 1-35 (all partially)

peptide consisting of SEQ ID NO:44, amino acids 1-8, 2-9 or 2-8 of said sequence, conjugate, viral vecor, nucleic acid, fusion protein, pharmaceutical composition comprising it and its method

---

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/14407

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0073478	A	07-12-2000	AU 5464000 A 18-12-2000
			EP 1181382 A2 27-02-2002
			JP 2003501041 T 14-01-2003
			WO 0073478 A2 07-12-2000
-----			
US 2003149235	A1	07-08-2003	NONE
-----			